Cargando…

The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy

STUDY DESIGN: Case-control study. OBJECTIVES: Cervical spondylotic myelopathy (CSM) is the most common cause of spinal cord injury in adults aged over 55 years. However, since the onset is typically insidious, accurately diagnosing CSM can be challenging, often requiring referral to a subspecialist...

Descripción completa

Detalles Bibliográficos
Autores principales: Barkoh, Kaku, Ohiorhenuan, Ifije E., Lee, Larry, Lucas, Joshua, Arakelyan, Anush, Ornelas, Christopher, Buser, Zorica, Hsieh, Patrick, Acosta, Frank, Liu, John, Wang, Jeffrey C., Hah, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693067/
https://www.ncbi.nlm.nih.gov/pubmed/31448193
http://dx.doi.org/10.1177/2192568218815863
_version_ 1783443640375312384
author Barkoh, Kaku
Ohiorhenuan, Ifije E.
Lee, Larry
Lucas, Joshua
Arakelyan, Anush
Ornelas, Christopher
Buser, Zorica
Hsieh, Patrick
Acosta, Frank
Liu, John
Wang, Jeffrey C.
Hah, Raymond
author_facet Barkoh, Kaku
Ohiorhenuan, Ifije E.
Lee, Larry
Lucas, Joshua
Arakelyan, Anush
Ornelas, Christopher
Buser, Zorica
Hsieh, Patrick
Acosta, Frank
Liu, John
Wang, Jeffrey C.
Hah, Raymond
author_sort Barkoh, Kaku
collection PubMed
description STUDY DESIGN: Case-control study. OBJECTIVES: Cervical spondylotic myelopathy (CSM) is the most common cause of spinal cord injury in adults aged over 55 years. However, since the onset is typically insidious, accurately diagnosing CSM can be challenging, often requiring referral to a subspecialist and advanced imaging. To help identify patients at risk for CSM, this case-control study compared responses to a series of 4 questions (DOWN questionnaire) in myelopathic and non-myelopathic patients. METHODS: Ninety-two patients, 46 with and 46 without myelopathy, were recruited for the study. Each patient answered 4 questions encompassing common symptoms associated with CSM. Responses between patient groups were compared, and Cohen’s κ was used to assess for agreement between responses and the diagnosis of myelopathy. RESULTS: We found a sensitivity of 91% and a κ of 0.54 to 3 positive responses and a sensitivity of 72% and a κ of 0.61 to 4 positive responses. CONCLUSIONS: Positive responses to 3 or more DOWN questions has high sensitivity and moderate agreement with the diagnosis of myelopathy based on history, physical exam, and review of advanced imaging by an orthopedic or neurological surgeon. The DOWN questionnaire is a potentially useful screening tool to identify patients at risk for CSM.
format Online
Article
Text
id pubmed-6693067
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-66930672019-08-23 The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy Barkoh, Kaku Ohiorhenuan, Ifije E. Lee, Larry Lucas, Joshua Arakelyan, Anush Ornelas, Christopher Buser, Zorica Hsieh, Patrick Acosta, Frank Liu, John Wang, Jeffrey C. Hah, Raymond Global Spine J Original Articles STUDY DESIGN: Case-control study. OBJECTIVES: Cervical spondylotic myelopathy (CSM) is the most common cause of spinal cord injury in adults aged over 55 years. However, since the onset is typically insidious, accurately diagnosing CSM can be challenging, often requiring referral to a subspecialist and advanced imaging. To help identify patients at risk for CSM, this case-control study compared responses to a series of 4 questions (DOWN questionnaire) in myelopathic and non-myelopathic patients. METHODS: Ninety-two patients, 46 with and 46 without myelopathy, were recruited for the study. Each patient answered 4 questions encompassing common symptoms associated with CSM. Responses between patient groups were compared, and Cohen’s κ was used to assess for agreement between responses and the diagnosis of myelopathy. RESULTS: We found a sensitivity of 91% and a κ of 0.54 to 3 positive responses and a sensitivity of 72% and a κ of 0.61 to 4 positive responses. CONCLUSIONS: Positive responses to 3 or more DOWN questions has high sensitivity and moderate agreement with the diagnosis of myelopathy based on history, physical exam, and review of advanced imaging by an orthopedic or neurological surgeon. The DOWN questionnaire is a potentially useful screening tool to identify patients at risk for CSM. SAGE Publications 2018-12-04 2019-09 /pmc/articles/PMC6693067/ /pubmed/31448193 http://dx.doi.org/10.1177/2192568218815863 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (http://www.creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Barkoh, Kaku
Ohiorhenuan, Ifije E.
Lee, Larry
Lucas, Joshua
Arakelyan, Anush
Ornelas, Christopher
Buser, Zorica
Hsieh, Patrick
Acosta, Frank
Liu, John
Wang, Jeffrey C.
Hah, Raymond
The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy
title The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy
title_full The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy
title_fullStr The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy
title_full_unstemmed The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy
title_short The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy
title_sort down questionnaire: a novel screening tool for cervical spondylotic myelopathy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693067/
https://www.ncbi.nlm.nih.gov/pubmed/31448193
http://dx.doi.org/10.1177/2192568218815863
work_keys_str_mv AT barkohkaku thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT ohiorhenuanifijee thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT leelarry thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT lucasjoshua thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT arakelyananush thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT ornelaschristopher thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT buserzorica thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT hsiehpatrick thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT acostafrank thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT liujohn thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT wangjeffreyc thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT hahraymond thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT barkohkaku downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT ohiorhenuanifijee downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT leelarry downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT lucasjoshua downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT arakelyananush downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT ornelaschristopher downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT buserzorica downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT hsiehpatrick downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT acostafrank downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT liujohn downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT wangjeffreyc downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy
AT hahraymond downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy